Literature DB >> 32891604

Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes.

Kohjiro Ueki1, Takayoshi Sasako2, Yukiko Okazaki3, Kana Miyake2, Masaomi Nangaku4, Yasuo Ohashi5, Mitsuhiko Noda6, Takashi Kadowaki7.   

Abstract

To evaluate the effect of multifactorial intervention on the onset and progression of diabetic kidney disease in the patients with type 2 diabetes, we analyzed the effects of intensified multifactorial intervention by step-wise intensification of medications and life-style modifications (intensive therapy treatment targets; HbA1c under 6.2%, blood pressure under 120/75 mmHg, low-density lipoprotein cholesterol under 80 mg/dL) comparing with the guideline-based standard care (conventional therapy treatment targets: HbA1c under 6.9%, blood pressure under 130/80 mmHg, low-density lipoprotein cholesterol under 120 mg/dL) on diabetic kidney disease. A total of 2540 eligible patients in the Japan Diabetes Optimal Integrated Treatment for three major risk factors of cardiovascular diseases (J-DOIT3) cohort were randomly assigned to intensive therapy (1269) and conventional therapy (1271) and treated for a median of 8.5 years. The prespecified kidney outcome measure was a composite of progression from normoalbuminuria to microalbuminuria or progression from normoalbuminuria to macroalbuminuria or progression from microalbuminuria to macroalbuminuria, serum creatinine levels elevated by two-fold or more compared to baseline, or kidney failure. Primary analysis was carried out on the intention-to-treat population. Changes in the estimated glomerular filtration rate and albuminuria were also analyzed. A total of 438 kidney events occurred (181 in the intensive therapy group and 257 in the conventional therapy group). Intensive therapy was associated with a significant 32% reduction in kidney events compared to conventional therapy and was associated with a change in HbA1c at one year from study initiation. Thus, prespecified analysis shows that intensified multifactorial intervention significantly reduced the onset and progression of diabetic kidney disease compared to currently recommended care.
Copyright © 2020 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  diabetes; hemodialysis; microalbuminuria

Mesh:

Year:  2020        PMID: 32891604     DOI: 10.1016/j.kint.2020.08.012

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  12 in total

1.  Eighteen-year trends in the management of patients with diabetes in the Shiga Diabetes Clinical Survey: overall trends and differences by age group.

Authors:  Itsuko Miyazawa; Hiroshi Maegawa; Aya Kadota; Takashi Nakamura; Makoto Konishi; Shinichi Ochi; Katsuyuki Miura; Motozumi Okamoto
Journal:  Diabetol Int       Date:  2022-02-17

2.  Relationship between compliance with management target values and renal prognosis in multidisciplinary care for outpatients with chronic kidney disease.

Authors:  Yoshihiko Imamura; Yasunori Takahashi; Takato Takeuchi; Masateru Iwamoto; Miki Yamauchi; Rie Nakamura; Yuka Ogawara; Kazuyo Takeba; Makoto Shinohara; Nobuhiko Joki
Journal:  Clin Exp Nephrol       Date:  2022-04-10       Impact factor: 2.617

3.  Initiating SGLT2 inhibitor therapy to improve renal outcomes for persons with diabetes eligible for an intensified glucose-lowering regimen: hypothetical intervention using parametric g-formula modeling.

Authors:  Masato Takeuchi; Masahito Ogura; Nobuya Inagaki; Koji Kawakami
Journal:  BMJ Open Diabetes Res Care       Date:  2022-06

4.  Incidence of end-stage renal disease and risk factors for progression of renal dysfunction in Japanese patients with type 2 diabetes: the Fukuoka Diabetes Registry.

Authors:  Masanori Iwase; Hitoshi Ide; Toshiaki Ohkuma; Hiroki Fujii; Yuji Komorita; Masahito Yoshinari; Yutaro Oku; Taiki Higashi; Udai Nakamura; Takanari Kitazono
Journal:  Clin Exp Nephrol       Date:  2021-09-28       Impact factor: 2.801

5.  The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials.

Authors:  Emilie H Zobel; Bernt Johan von Scholten; Tine W Hansen; Frederik Persson; Søren Rasmussen; Benjamin Wolthers; Peter Rossing
Journal:  Diabetes Obes Metab       Date:  2021-11-05       Impact factor: 6.408

Review 6.  Renoprotective Effects of DPP-4 Inhibitors.

Authors:  Daiji Kawanami; Yuichi Takashi; Hiroyuki Takahashi; Ryoko Motonaga; Makito Tanabe
Journal:  Antioxidants (Basel)       Date:  2021-02-05

Review 7.  Treatment of Diabetic Kidney Disease: Current and Future.

Authors:  Tomotaka Yamazaki; Imari Mimura; Tetsuhiro Tanaka; Masaomi Nangaku
Journal:  Diabetes Metab J       Date:  2021-01-22       Impact factor: 5.376

8.  Effect of a Multifactorial Intervention on Fracture in Patients With Type 2 Diabetes: Subanalysis of the J-DOIT3 Study.

Authors:  Takayoshi Sasako; Kohjiro Ueki; Kana Miyake; Yukiko Okazaki; Yasuhiro Takeuchi; Yasuo Ohashi; Mitsuhiko Noda; Takashi Kadowaki
Journal:  J Clin Endocrinol Metab       Date:  2021-04-23       Impact factor: 5.958

9.  Berberine regulates mesangial cell proliferation and cell cycle to attenuate diabetic nephropathy through the PI3K/Akt/AS160/GLUT1 signalling pathway.

Authors:  Wei-Jian Ni; Xi-Mei Guan; Jing Zeng; Hong Zhou; Xiao-Ming Meng; Li-Qin Tang
Journal:  J Cell Mol Med       Date:  2022-01-09       Impact factor: 5.310

10.  Effect of a Web-Based Management Guide on Risk Factors in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A JADE Randomized Clinical Trial.

Authors:  Juliana C N Chan; Yotsapon Thewjitcharoen; Thy Khue Nguyen; Alexander Tan; Yook-Chin Chia; Chii-Min Hwu; Du Jian; Thep Himathongkam; Kim-Leng Wong; Yun-Mi Choi; Roberto Mirasol; Mafauzy Mohamed; Alice P S Kong; Ronald C W Ma; Elaine Y K Chow; Risa Ozaki; Vanessa Lau; Amy W C Fu; Eun-Gyoung Hong; Kun-Ho Yoon; Chiu-Chi Tsang; Eric S H Lau; Lee-Ling Lim; Andrea O Y Luk
Journal:  JAMA Netw Open       Date:  2022-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.